Extract
Traditional asthma maintenance therapy in adults and adolescents comprises inhaled corticosteroids (ICS), with a long-acting β2-agonist (LABA) added if ICS monotherapy provides insufficient control [1, 2]. For patients with symptoms occurring on two or fewer occasions per week (so-called “intermittent” asthma [2]), who may represent around one-third of the asthma population [3], many guidelines still recommend short-acting β2-agonist (SABA) rescue medication alone [2, 4].
Abstract
These post hoc analyses of NovelSTART provide the first evidence that the exacerbation risk reduction with budesonide–formoterol reliever therapy versus salbutamol reliever therapy is similar in adults with intermittent and mild persistent asthma https://bit.ly/3iiRKqR
Acknowledgements
Writing support was provided by David Young of Young Medical Communications and Consulting Ltd. This was funded by Consorzio Futuro in Ricerca, University of Ferrara, Ferrara, Italy.
Footnotes
This study is registered at the Australian New Zealand Clinical Trials Registry, number ACTRN12615000999538. Deidentified patient data will be made available to researchers whose proposed use of the data has been approved by the NovelSTART Steering Committee on request to the corresponding author.
Conflict of interest: A. Papi reports grants and personal fees from MRINZ, during the conduct of the study; grants, personal fees for advisory board work, consultancy and lectures, and non-financial support for travel and meeting attendance from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and TEVA, personal fees for advisory board work, consultancy and lectures, and non-financial support for travel and meeting attendance from Mundipharma, Zambon, Sanofi/Regeneron and Novartis, grants, personal fees for lectures and non-financial support for travel and meeting attendance from Menarini, personal fees for advisory board work, consultancy and non-financial support for travel and meeting attendance from Roche, grants from Fondazione Maugeri and Fondazione Chiesi, personal fees for consultancy from Edmondpharma, outside the submitted work.
Conflict of interest: I. Braithwaite reports grants from AstraZeneca and Health Research Council of New Zealand, during the conduct of the study.
Conflict of interest: S. Ebmeier reports grants from MRINZ, during the conduct of the study.
Conflict of interest: R.J. Hancox reports personal fees for lectures from Menarini, personal fees for lectures and support for meeting attendance from AstraZeneca, support for meeting attendance from Boehringer Ingelheim, during the conduct of the study.
Conflict of interest: T. Harrison reports grants from MRINZ, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from GSK, personal fees from Vectura, Synairgen and Chiesi, outside the submitted work.
Conflict of interest: M. Holliday reports grants from Health Research Council of New Zealand and AstraZeneca, during the conduct of the study.
Conflict of interest: C. Houghton reports grants from Health Research Council of New Zealand and AstraZeneca, during the conduct of the study.
Conflict of interest: L. Morandi reports grants from MRINZ, during the conduct of the study.
Conflict of interest: K. Oldfield reports grants to MRINZ from the Health Research Council of New Zealand, grants from AstraZeneca, during the conduct of the study.
Conflict of interest: I.D. Pavord reports personal fees for lectures, advisory board work, meeting attendance and educational activities from AstraZeneca, personal fees for lectures, advisory board work and meeting attendance from Boehringer Ingelheim and GlaxoSmithKline, personal fees for lectures from Aerocrine and Chiesi, personal fees for lectures and advisory board work from Almirall and Novartis, personal fees for advisory board work from Genentech, Regeneron, Sanofi, Circassia and Knopp, personal fees for lectures, meeting attendance and educational activities from Teva, grants from NIHR, outside the submitted work.
Conflict of interest: H.K. Reddel reports grants from AstraZeneca and Health Research Council of New Zealand, during the conduct of the study; grants and personal fees for advisory board and data committee work, and for educational activities from AstraZeneca and GlaxoSmithKline, personal fees for data monitoring committee work from Merck, grants and personal fees for data monitoring committee and advisory board work from Novartis, personal fees for educational activities from Teva, personal fees for educational activities and advisory board work from Boehringer Ingelheim, personal fees for advisory board work from Sanofi Genzyme, outside the submitted work; and is Chair of the GINA Science Committee.
Conflict of interest: M. Williams reports grants from MRINZ, during the conduct of the study; personal fees from Genentech Respiratory Operational Review Board, outside the submitted work.
Conflict of interest: M. Weatherall has nothing to disclose.
Conflict of interest: R. Beasley reports grants from Health Research Council of New Zealand and AstraZeneca, during the conduct of the study; grants and personal fees for lectures, advisory board work and meeting attendance from AstraZeneca, grants from GlaxoSmithKline and Genentech, personal fees for advisory board work from Theravance Biopharma, outside the submitted work.
Support statement: The global sponsor of NovelSTART was the Medical Research Institute of New Zealand (Wellington, New Zealand); the study was funded by AstraZeneca. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received June 4, 2020.
- Accepted September 23, 2020.
- Copyright ©ERS 2021
LIBRARY USERS
Log in through your institution
Purchase access
